Don't Just Read the News, Understand It.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Juneteenth
Social Media
Evacuations
Artificial Intelligence
Donald Trump
Education
MLB
Infrastructure
War
World Cup
Crime
Immigration
Published • loading... • Updated

Dyne pivots on primary endpoint, delays filing for DM1 drug

Summary by endpoints.news
Dyne Therapeutics met with the FDA to discuss what's needed for the accelerated approval of its myotonic dystrophy drug, and it settled on a different primary endpoint than expected. The company also
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
endpoints.newsendpoints.news

Dyne pivots on primary endpoint, delays filing for DM1 drug

Dyne Therapeutics met with the FDA to discuss what's needed for the accelerated approval of its myotonic dystrophy drug, and it settled on a different primary endpoint than expected. The company also

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Tuesday, June 17, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal